Navigation Links
Celladon Corporation Receives FDA Fast Track Designation for Its Investigational Agent MYDICAR® for the Treatment of Heart Failure
Date:12/12/2011

LA JOLLA, Calif., Dec. 12, 2011 /PRNewswire/ -- Celladon Corp., a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, announced today that its investigational product candidate MYDICAR® has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of advanced heart failure.

The Fast Track program of the FDA is designed to facilitate the development and expedite the review of new drugs that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs.

"The positive results of the phase 2 CUPID Trial demonstrated the potential of MYDICAR® to become an important treatment for patients with chronic, advanced heart failure," said Krisztina Zsebo Ph.D., President and CEO of Celladon Corp.  Dr. Zsebo continued, "Today we are pleased that the FDA recognizes the potential benefit of MYDICAR® to address the enormous unmet medical need for additional therapeutics to treat advanced heart failure patients by granting the program Fast Track Status."

About the CUPID Trial

The previously announced results of the phase 2 CUPID Trial met its primary safety and efficacy endpoints at 6 months for high dose MYDICAR® versus placebo. Additionally, 12 months after receiving a single infusion of MYDICAR®, patients treated with the highest dose versus placebo had an 88 percent risk reduction (Hazard Ratio = 0.12, P=0.003) of major cardiovascular events such as death, need for left ventricular assist device (LVAD) or cardiac transplant, episodes of worsening heart failure and number of heart failure-related hospitalizations.

The mean duration of hospitalization in the MYDICAR® high dose group during the 12-month period was 0.4 days per patient compared with 4.5 days per patient in the placebo group. This finding is especially n
'/>"/>

SOURCE Celladon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Celladon Corporation Announces MYDICAR® Enzyme Replacement Therapy for Advanced Heart Failure Provides Sustained Reduction in Clinical Events in Patients for 18 Months Compared with Placebo
2. Celladon Provides MYDICAR(R) Program Update of First-In-Human Trial for Advanced Heart Failure at American Society of Gene Therapy Annual Meeting
3. Celladon Corporation Announces Presentation of First-in-Human Gene Transfer to Treat Heart Failure at the 12th Annual Meeting of the American Society of Gene Therapy
4. Celladon Announces Presentation of Clinical Data From First-in-Human MYDICAR(R) Trial for Advanced Heart Failure at American Heart Association Scientific Sessions
5. Leatt Corporation Announces 2011 Annual Shareholders Meeting
6. Angeion Corporation to Report Fourth Quarter and Fiscal Year 2011 Financial Results on Friday, December 16, 2011
7. Radient Pharmaceuticals Corporation Receives $500,000 in New Capital
8. Radient Pharmaceuticals Corporation Completes Restructurings with Institutional Investors to Limit Conversions and Stock Sales and Provide for Potential Additional Capital
9. China Cord Blood Corporation Reports Financial Results for the Second Quarter and First Half of Fiscal 2012
10. Ansell Limited Acquires a Minority Share in Yulex Corporation
11. The Female Health Companys Distributor, Sekunjalo Investments Corporation (PTY) Ltd., Receives Order for 5 Million FC2 Female Condoms From the Republic of South Africa Department of Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... Aug. 4, 2015 ANI Pharmaceuticals, Inc. ("ANI") ... the three and six months ended June 30, 2015 ... will host its earnings conference call this morning, August ... interested parties can join the call by dialing (855) ... Highlights Include: , Year-to-date net revenues of $38.3 million, ...
(Date:8/3/2015)... Utah , Aug. 3, 2015  BC Technical, the ... acquired Ohio Valley Medical Systems, one of the largest ...  The addition of Ohio Valley Medical Systems allows BC ... include Hitachi MRI.   "We couldn,t be ... , President and CEO of BC Technical. "The Ohio ...
(Date:8/3/2015)... MINNEAPOLIS , Aug. 3, 2015 /PRNewswire/ ... a significant shareholder and will become the exclusive ... for cardiology-related diagnostic and monitoring offerings. ... for Preventice Solutions," said Jon Otterstatter , ... Preventice Solutions.  "We are thrilled to partner with ...
Breaking Medicine Technology:ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 2ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 3ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 4ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 5ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 6ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 7ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 8ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 9ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 10ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 11ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 12ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 13ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 14ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 15ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 16BC Technical Acquires Ohio Valley Medical Systems 2Boston Scientific Announces Equity Investment And Sales Cooperation Agreement With Preventice Solutions 2
(Date:8/4/2015)... ... August 04, 2015 , ... NutraScience ... packaging, and fulfillment services, joined over 200 other Long Island-based corporations as participants ... Tuesday, July 28th at Jones Beach State Park in Wantagh, New York. , ...
(Date:8/4/2015)... & Montclair, NJ (PRWEB) , ... August 04, 2015 , ... ... program in Arts and Health, the first of its kind in New Jersey, which ... University’s College of the Arts and Graduate School partnered with Atlantic Health System, one ...
(Date:8/4/2015)... ... August 04, 2015 , ... Sin ... unique artistic expressions from a diverse group of exceptionally talented female artists. ... & Art Festival on September 25-27, 2015 in Downtown Las Vegas. Curated by ...
(Date:8/4/2015)... ... August 04, 2015 , ... Driving skills ... end to driving, says the August 2015 Harvard Health Letter. , "Age and ... It requires an individual assessment of skills," says Lissa Kapust, a social worker ...
(Date:8/4/2015)... Meadows, Ill. (PRWEB) , ... August 04, 2015 ... ... procedure and the specialty in which the physician is board-certified is increasingly influential ... Society for Dermatologic Surgery. , The 2015 ASDS Consumer Survey on Cosmetic Dermatologic ...
Breaking Medicine News(10 mins):Health News:NutraScience Labs "Steps Up" to the 2015 Marcum Workplace Challenge 2Health News:Atlantic Health System & Montclair State University Launch Graduate Program in Arts & Health 2Health News:Atlantic Health System & Montclair State University Launch Graduate Program in Arts & Health 3Health News:Sin City Gallery Rocks Life Is Beautiful Festival with INTIMATELY FEMALE at Art Motel 2Health News:Sin City Gallery Rocks Life Is Beautiful Festival with INTIMATELY FEMALE at Art Motel 3Health News:Sin City Gallery Rocks Life Is Beautiful Festival with INTIMATELY FEMALE at Art Motel 4Health News:Assessment Can Help Older Drivers Keep Driving Safely, from the August 2015 Harvard Health Letter 2Health News:ASDS Survey: Half of Consumers Considering Cosmetic Procedure 2Health News:ASDS Survey: Half of Consumers Considering Cosmetic Procedure 3Health News:ASDS Survey: Half of Consumers Considering Cosmetic Procedure 4
... Bio-Reaction Industries, LLC (BRI),received the Gold medal ... the Environmental Business Journal for 2008. This award ... as a worldwide leader of,bio-oxidation technology. , ... in 2008, increasing,revenue by 300% for the second ...
... 9% Over 2007 to $765.3 Million; Positive Operating Cash ... 27 Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ... year ended December 31, 2008. The Company reported total ... 31, 2008, which includes net product sales of $184.9 ...
... chronic disease crisisWASHINGTON, Jan. 27 The Partnership ... Obama and Congress to make health reform a ... efforts. Topping its list of "Principles for Meaningful ... incentives in the health care system to encourage ...
... could help treat depression, other disorders, researchers say , , ... scientists say they,ve devised a potential new method ... the natural dynamics of the body,s "fight or flight" ... adrenal (HPA) axis, one of the body,s major control ...
... study notes, , , TUESDAY, Jan. 27 (HealthDay News) -- ... age of 40 who had chest radiation as part ... to get screening mammograms sooner than other women, new ... at age 25, or 8 years after the last ...
... OMCL ) a leading provider of system solutions to ... Duke University Health,System for Omnicell medication point-of-use and ... University Health System is comprised of Duke University ... clinical,facilities. , About Omnicell , ...
Cached Medicine News:Health News:Bio-Reaction Industries Recognized as Leader in Technology 2Health News:Amylin Pharmaceuticals Reports 2008 Financial Results 2Health News:Amylin Pharmaceuticals Reports 2008 Financial Results 3Health News:Amylin Pharmaceuticals Reports 2008 Financial Results 4Health News:Amylin Pharmaceuticals Reports 2008 Financial Results 5Health News:Amylin Pharmaceuticals Reports 2008 Financial Results 6Health News:Amylin Pharmaceuticals Reports 2008 Financial Results 7Health News:Amylin Pharmaceuticals Reports 2008 Financial Results 8Health News:Amylin Pharmaceuticals Reports 2008 Financial Results 9Health News:Amylin Pharmaceuticals Reports 2008 Financial Results 10Health News:National Partnership Releases Principles for Meaningful Health Reform 2Health News:Childhood Cancer Survivors Not Getting Recommended Mammograms 2Health News:Childhood Cancer Survivors Not Getting Recommended Mammograms 3Health News:Omnicell is Awarded Contract by Major National Academic Medical Center 2
Luria bertani broth: 1.0% Tryptone, 0.5% Yeast Extract, 1.0% Sodium Chloride....
2.5% Soytone, 4.8% Yeast Extract, 0.025% Magnesium Sulfate, 130mM Calcium Chloride....
12% Tryptone, 24% Yeast Extract, 4.0% Glycerol. Supplied with 1 liter of 10x phosphate buffer (0190-1L)....
1.0% Casein digest (NZ amine), 0.5% Sodium Chloride, 0.5% Yeast Extract, 1.0% bacto casamino acids, 0.2% Mag. Sulfate....
Medicine Products: